Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease

doi:10.3389/fmed.2022.921631

	Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease
	Xu, Jing 1,2; Xue, Cheng 1; Wang, Xiaodong2,3 ; Zhang, Lei2,3,4 ; Mei, Changlin 1; Mao, Zhiguo 1
	2022-07-05
发表期刊	FRONTIERS IN MEDICINE (IF:3.1[JCR-2023],3.4[5-Year])
EISSN	2296-858X
卷号	9
发表状态	已发表
DOI	10.3389/fmed.2022.921631
摘要	Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease worldwide and is one of the major causes of end-stage renal disease. PKD1 and PKD2 are two genes that mainly contribute to the development and progression of ADPKD. The precise mechanism is not fully understood. In recent years, epigenetic modification has drawn increasing attention. Chromatin methylation is a very important category of PKD epigenetic changes and mostly involves DNA, histone, and RNA methylation. Genome hypomethylation and regional gene hypermethylation coexist in ADPKD. We found that the genomic DNA of ADPKD kidney tissues showed extensive demethylation by whole-genome bisulphite sequencing, while some regional DNA methylation from body fluids, such as blood and urine, can be used as diagnostic or prognostic biomarkers to predict PKD progression. Histone modifications construct the histone code mediated by histone methyltransferases and contribute to aberrant methylation changes in PKD. Considering the complexity of methylation abnormalities occurring in different regions and genes on the PKD epigenome, more specific therapy aiming to restore to the normal genome should lead to the development of epigenetic treatment.
关键词	DNA methylation histone methylation RNA methylation autosomal dominant polycystic kidney disease epigenetics
URL	查看原文
收录类别	SCI ; SCIE
语种	英语
资助项目	National Natural Science Foundation of China["82070705","81770670","81873595","32030025"] ; National Key Research and Development Program of China[2019YFA0802001] ; Shanghai Municipal Key Clinical Specialty[shslczdzk02503] ; Shanghai Science and Technology Talent Program[19YF1450300] ; Research Projects of Shanghai Science and Technology Committee[17411972100]
WOS研究方向	General & Internal Medicine
WOS类目	Medicine, General & Internal
WOS记录号	WOS:000828670000001
出版者	FRONTIERS MEDIA SA
引用统计	正在获取...
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/214796
专题	生命科学与技术学院_特聘教授组_张雷组生命科学与技术学院_博士生
通讯作者	Zhang, Lei; Mei, Changlin; Mao, Zhiguo
作者单位	1.Second Mil Med Univ, Shanghai Changzheng Hosp, Kidney Inst, Dept Nephrol, Shanghai, Peoples R China 2.Univ Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Ctr Excellence Mol Cell Sci, Shanghai, Peoples R China 3.Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China 4.Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Life Sci, Hangzhou, Peoples R China
通讯作者单位	生命科学与技术学院
推荐引用方式 GB/T 7714	Xu, Jing,Xue, Cheng,Wang, Xiaodong,et al. Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease[J]. FRONTIERS IN MEDICINE,2022,9.
APA	Xu, Jing,Xue, Cheng,Wang, Xiaodong,Zhang, Lei,Mei, Changlin,&Mao, Zhiguo.(2022).Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease.FRONTIERS IN MEDICINE,9.
MLA	Xu, Jing,et al."Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease".FRONTIERS IN MEDICINE 9(2022).